ENDPOINTS

Akeso shares new data for bispecific in cervical cancer; Pulmatrix to divest assets

+Plus, news about Autolus, MacroGenics and BlissBio: Akeso bispecific looks promising in cervical cancer: The China-based biotech said Friday that all patients in a Phase 3 cervical cancer trial responded to ...

Mar 21, 2025 - 16:30
 0
Akeso shares new data for bispecific in cervical cancer; Pulmatrix to divest assets
+Plus, news about Autolus, MacroGenics and BlissBio: Akeso bispecific looks promising in cervical cancer: The China-based biotech said Friday that all patients in a Phase 3 cervical cancer trial responded to ...
Read More

Tags:

Previous Article

AstraZeneca earmarks $2.5B for first vaccine factory and second R&D site in China

Next Article

NASA to Cover Northrop Grumman’s 21st Cargo Space Station Departure

Related Posts

AstraZeneca inks deal with Alteogen for subcutaneous cancer drugs

AstraZeneca inks deal with Alteogen for subcutaneous ca...

Mar 17, 2025  0

Lilly-partnered Fauna Bio plans $40M Series A to get into heart failure

Lilly-partnered Fauna Bio plans $40M Series A to get in...

Mar 14, 2025  0

AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron

AstraZeneca broadens presence in China, promising $8B+ ...

Mar 21, 2025  0